World Health Organization site
Skip Navigation Links
Home
Advanced Search
List ByExpand List By
Search Tips
UTNExpand UTN
ICTRP websiteExpand ICTRP website
Contact us
                   239 records for 94 trials found!
Trials are sometimes recorded in more than one registry. These records can refer to each other using the 'Secondary ID' field. The search portal uses these Secondary IDs to group records about the same trial together in the search results.
Each group of records referring to a trial is displayed in table that is seen by pressing the + symbol. The record with the earliest date of registration is always shown first.
 
 
 
 
  Showrecords per page     

1 2 3 4 5 6 7 8 9 10
Recruitment statusMain ID Public TitleDate of Registration
AuthorisedEUCTR2013-004148-49-HU
RANDOMIZED STUDY OF PF-06438179 AND INFLIXIMAB IN COMBINATION WITH METHOTREXATE IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2013-004148-49-DERANDOMIZED STUDY OF PF-06438179 AND INFLIXIMAB IN COMBINATION WITH METHOTREXATE IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS06/06/2014
06/06/2014
Not AvailableEUCTR2013-000261-36-Outside-EU/EEA
A fibrinogen concentrate study in paediatric patients with inherited fibrinogen deficiency
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2013-000261-36-FRA fibrinogen concentrate study in paediatric patients with inherited fibrinogen deficiency04/04/2014
04/04/2014
Not RecruitingCTRI/2014/03/004443
A clinical study of EVERolimus (RAD001)in combination with EXemestane in post-menopausal women with EStrogen receptor positive, human epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer
05-03-2014
RecruitingNCT02094430
Human Fibrinogen Concentrate (FGTW) in Pediatric Patients With Congenital Fibrinogen Deficiency
26/02/2014
AuthorisedEUCTR2013-002293-41-SK
Study to evaluate 2 types of treatment as first line treatment (masitinib + gemcitabine or placebo + gemcitabine ) and 2 types of treatment as second line treatment (masitinib + FOLFIRI 3 or placebo + FOLFIRI 3) in the treatment of patients with with non resectable locally advanced or metastatic pancreatic cancer.
19/02/2014
Not RecruitingEUCTR2013-002351-15-EE
Study which compares the effectiveness and safety of a not yet approved drug called ONO-4641 versus an approved drug called interferon beta 1a (active comparator) in patients with multiple sclerosis. The study is double-blind (that is when neither the patient nor the investigator know which of the 2 drugs the patient is receiving). Patients will be randomly assigned (like the flip of a coin) to receive the study drug (two different doses) or the comparator.
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2013-002351-15-ATStudy which compares the effectiveness and safety of a not yet approved drug called ONO-4641 versus an approved drug called interferon beta 1a (active comparator) in patients with multiple sclerosis. The study is double-blind (that is when neither the patient nor the investigator know which of the 2 drugs the patient is receiving). Patients will be randomly assigned (like the flip of a coin) to receive the study drug (two different doses) or the comparator. 28/02/2014
AuthorisedEUCTR2013-002351-15-LVStudy which compares the effectiveness and safety of a not yet approved drug called ONO-4641 versus an approved drug called interferon beta 1a (active comparator) in patients with multiple sclerosis. The study is double-blind (that is when neither the patient nor the investigator know which of the 2 drugs the patient is receiving). Patients will be randomly assigned (like the flip of a coin) to receive the study drug (two different doses) or the comparator. 20/02/2014
AuthorisedEUCTR2013-002351-15-HUStudy which compares the effectiveness and safety of a not yet approved drug called ONO-4641 versus an approved drug called interferon beta 1a (active comparator) in patients with multiple sclerosis. The study is double-blind (that is when neither the patient nor the investigator know which of the 2 drugs the patient is receiving). Patients will be randomly assigned (like the flip of a coin) to receive the study drug (two different doses) or the comparator. 21/02/2014
AuthorisedEUCTR2013-002351-15-PTStudy which compares the effectiveness and safety of a not yet approved drug called ONO-4641 versus an approved drug called interferon beta 1a (active comparator) in patients with multiple sclerosis. The study is double-blind (that is when neither the patient nor the investigator know which of the 2 drugs the patient is receiving). Patients will be randomly assigned (like the flip of a coin) to receive the study drug (two different doses) or the comparator. 25/02/2014
Not RecruitingEUCTR2013-002351-15-BGStudy which compares the effectiveness and safety of a not yet approved drug called ONO-4641 versus an approved drug called interferon beta 1a (active comparator) in patients with multiple sclerosis. The study is double-blind (that is when neither the patient nor the investigator know which of the 2 drugs the patient is receiving). Patients will be randomly assigned (like the flip of a coin) to receive the study drug (two different doses) or the comparator. 20/02/2014
Not RecruitingEUCTR2013-002351-15-ESStudy which compares the effectiveness and safety of a not yet approved drug called ONO-4641 versus an approved drug called interferon beta 1a (active comparator) in patients with multiple sclerosis. The study is double-blind (that is when neither the patient nor the investigator know which of the 2 drugs the patient is receiving). Patients will be randomly assigned (like the flip of a coin) to receive the study drug (two different doses) or the comparator.25/02/2014
18/02/2014
AuthorisedEUCTR2012-004222-25-SK
Comparison of efficacy of masitinib versus placebo in the treatment of Crohn's disease
09/01/2014
AuthorisedEUCTR2013-003997-28-GB
Study to collect data to further monitor whether the treatment triggers an immune reaction (i.e. development of antibodies, so called “inhibitors” directed against factor 8), to further investigate how well Human-cl rhFVIII prevents and stops bleeding episodes, and to monitor if it is safe and well tolerated in the treatment on a long-term basis. 20/11/2013
Not recruitingNCT01991340
H.E.R.O.S. Study: An Observational Study of the Cardiac Safety of Herceptin (Trastuzumab) in Patients With HER2-Positive Breast Cancer
07/11/2013
Not recruitingNCT01985204
Iodine Supplementation in Obesity
31/10/2013
    
1 2 3 4 5 6 7 8 9 10
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.2 - Version history